Here are our top 10 things to watch in the stock market Monday

AI semiconductor and infrastructure stocks face heavy premarket pressure after Anthropic CEO Dario Amodei called for a globally coordinated slowdown in AI-model development, a view supported publicly by OpenAI's Sam Altman and Elon Musk. WTI and Brent crude rose roughly 3% to above $100 per barrel after Saudi Arabia shut a pipeline bypassing the Strait of Hormuz, lifting bond yields and reinforcing expectations for a Federal Reserve rate increase this week. Separately, Johnson & Johnson is in talks to sell its DePuy Synthes orthopedics business to Apollo for about $20 billion, while Corning fell more than 8% after announcing a $2 billion at-the-market equity program.

Analysis

The AI selloff should be read as a duration and capital-intensity reset rather than a uniform impairment of AI earnings. Near-term downside is greatest in suppliers priced on multi-year hyperscaler capex assumptions—GLW is particularly exposed because an equity raise removes a balance-sheet support while the market is reassessing data-center demand. Conversely, CRWD can outperform semis if enterprise budgets rotate from experimental model deployment toward mandatory governance, identity and endpoint controls; the key verification point is whether management raises net-new ARR or remaining-performance-obligation expectations, not social-media safety commentary.

Oil above $100 creates a problematic cross-asset mix: higher fuel costs pressure discretionary retail gross margins and household demand while higher nominal yields compress long-duration multiples. NKE, DKS, UA and GOOS have asymmetric downside into holiday inventory commitments, especially if freight and promotional activity rise simultaneously. This is not yet a broad consumer short: a rapid oil reversal or a dovish Fed response would quickly relieve the rate and gasoline-tax headwind.

JNJ’s prospective orthopedics monetization would be more consequential as a capital-allocation event than as a growth driver. A clean sale to APO could support JNJ’s valuation through mix improvement and buyback capacity, while APO gains a long-duration fee-bearing asset platform; however, value creation depends on sale multiple, tax leakage and whether proceeds are directed to accretive bolt-ons rather than merely offsetting slower medtech growth. AFRM’s upgrade is tactically vulnerable: a higher-for-longer rate backdrop raises funding costs and credit-loss sensitivity, so multiple expansion requires evidence that transaction-margin gains exceed those offsets.

Key Decisions for Investors

• Initiate a 1-3 month pair: long CRWD / short GLW in equal dollar amounts. The trade expresses rotation from speculative infrastructure capex to security spend; stop if CRWD net-new ARR decelerates materially or GLW provides data-center demand visibility that offsets dilution.
• Reduce or hedge discretionary exposure through a basket short of UA and GOOS versus long XLE for the next 4-8 weeks. Oil-driven fuel inflation and yield pressure should hurt lower-pricing-power apparel first; cover if WTI falls below $90 or retail sales materially exceed expectations.
• Buy JNJ on confirmation of a signed transaction only, not on preliminary reports; target a 6-12 month re-rating from improved mix and capital deployment. Falsifier: proceeds below the implied $20B valuation, adverse tax treatment, or guidance indicating dilution to adjusted EPS.
• Avoid chasing AFRM on the analyst upgrade; use a break above the upgrade-day high only after funding-cost and delinquency data confirm improving unit economics. A long is invalidated by rising 30+ day delinquencies or sequential compression in transaction margin excluding provisions.
• Keep GE Aerospace underweight into the next aftermarket update. The downgrade matters only if utilization and spare-parts growth decelerate together; re-enter if service revenue growth remains resilient and free-cash-flow guidance is maintained.